Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Can-Fite BioPharma ( (CANF) ) has shared an update.
On March 4, 2026, Can-Fite BioPharma reported that its Phase 2a open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma who had failed prior systemic therapies successfully met its primary endpoint of safety. Namodenoson was very well tolerated with no new safety signals in this heavily pretreated, high-risk cohort of 20 patients, supporting further clinical development.
Secondary endpoints included overall survival and progression-free survival, with survival follow-up still ongoing and about one-third of patients alive at the data cut-off. Namodenoson, a selective A3 adenosine receptor agonist with preclinical anti-tumor activity in pancreatic cancer and ongoing trials in advanced liver cancer, holds Orphan Drug Designation for pancreatic cancer, underscoring its potential strategic value in Can-Fite’s oncology portfolio.
The most recent analyst rating on (CANF) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, declining revenue, and negative free cash flow) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Valuation impact is neutral because P/E and dividend data are not available.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company developing proprietary small-molecule drugs targeting multi-billion-dollar markets in cancer, liver and inflammatory diseases. Its lead candidates include piclidenoson for psoriasis and namodenoson for hepatocellular carcinoma and metabolic dysfunction-associated steatohepatitis, alongside additional oncology and erectile dysfunction programs, with more than 1,600 patients treated in trials to date.
Average Trading Volume: 223,711
Technical Sentiment Signal: Sell
Current Market Cap: $6.24M
For detailed information about CANF stock, go to TipRanks’ Stock Analysis page.